Perhaps some may see it as a bit unseemly, that I might mention this financial turn of fortune — in part, from dire circumstances, onboard that stricken liner. That is not my intent — at all.

As a point of five year fact, do recall that Moderna traded up to $340-ish, during the teeth of the COVID pandemic.

Then, in my view, Wall Street foolishly abandoned the company, after the emergency waned. It fell to the low $20s — and, in my mind — that was a screaming buy. [So this (mine) is about a sober, long term view.] Here’s a bit of the latest — and, in any event it is over $53 as I write this:

. . .Moderna is the Cambridge, Massachusetts-based biotechnology company that perfected messenger RNA (mRNA) vaccines during the Covid-19 pandemic. Following the announcement that Moderna was developing a hantavirus vaccine using this same technology, the drugmaker’s stock rose from $49 on May 7 to $55 the next day. But it is important to note that Moderna did not begin work on immunization in the wake of the outbreak at MV Hondius. In fact, the drugmaker undertook this collaborative project with VIC-K in 2023. . . .

It has come in a bit — but this is why I see it as a long term must have, in a life-science portfolio. As I’ve long said — this is (very conservatively). . . an $85 plus dollar stock, right now — even without an approved mRNA hanta- vaccine.

Much more, once approved — so. . . perhaps a ~$100 stock, once again, by next year(?). We shall see. Onward.

नमस्ते